Methods and compositions for treating allergic ocular diseases

Abstract

The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application Ser. No. 62 / 502,479, filed May 5, 2017, the disclosure of which is incorporated herein by reference in its entirety.SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE[0002]The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 701712000740SEQLIST.TXT, date recorded: May 3, 2018, size: 115 KB).FIELD OF THE INVENTION[0003]The present disclosure relates to methods for treating an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis) by administration of antibodies that bind to human Siglec-8 and compositions comprising said antibodies.BACKGROUND[0004]Allergic ocular diseases represent some of the most common ocular diseases. The number of people afflicted with allergic ocular diseases has risen in t...

AI Technical Summary

Benefits of technology

The present patent relates to methods for treating or preventing allergic ocular diseases, such as allergic conjunctivitis, by administering antibodies that bind to human Siglec-8. The methods involve administering the antibodies to an individual in need thereof, either by intravenous infusion or subcutaneous injection. The antibodies can be specific to certain allergens or can be used in a combination of antibodies. The treatment can reduce symptoms such as conjunctival itching, redness, swelling, ocular discharge, and tearing, as well as reduce the risk of developing other allergic diseases. The patent also provides methods for diagnosing and testing the effectiveness of the treatment.

Problems solved by technology

In some embodiments, an epicutaneous or intracutaneous allergy test administered to the individual using an allergen results in an allergic response.